Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Leuven, Belgien, 3000
- UZ Leuven
-
-
-
-
-
Berlin, Deutschland, 13125
- Charité - Campus Virchow-Klinikum
-
Hannover, Deutschland, 30625
- Medizinische Hochschule Hannover
-
Jena, Deutschland, 07743
- Universitaetsklinikum Jena
-
Ulm, Deutschland, 89081
- Universitaetsklinikum Ulm
-
-
-
-
Hérault
-
Montpellier, Hérault, Frankreich, 34295
- Hopital Gui de Chauliac, Service de Neurologie
-
-
Paris
-
Paris cedex 13, Paris, Frankreich, 75013
- Groupe Hospitalier Pitie-Salpetriere
-
-
-
-
-
Dublin, Irland, Dublin 9
- Beaumont Hospital
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montréal, Quebec, Kanada, H3A 2B4
- Montreal Neurological Institute Clinical Research Unit
-
-
-
-
CX
-
Utrecht, CX, Niederlande, 3584
- UMC Utrecht
-
-
-
-
-
St. Gallen, Schweiz, 9007
- Kantonsspital St. Gallen
-
-
-
-
California
-
San Diego, California, Vereinigte Staaten, 92103
- University of California San Diego Medical Center
-
San Francisco, California, Vereinigte Staaten, 94115
- California Pacific Medical Center
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- University of South Florida
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- The Emory Clinic
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins Hospital
-
-
Massachusetts
-
Charlestown, Massachusetts, Vereinigte Staaten, 2129
- Massachusetts General Hospital, MA
-
-
Missouri
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, EC037
- Penn State Milton S. Hershey Medical Center
-
-
-
-
West Midlands
-
Sheffield, West Midlands, Vereinigtes Königreich, S102JF
- Royal Hallamshire Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Key Inclusion Criteria:
- A diagnosis of sporadic or familial ALS
- ALS onset within ≤5 years
- Must be 16 to 85 years of age, inclusive, for sites in the United States and 18 to 85 years of age, inclusive, for all sites outside of the United States
Key Exclusion Criteria:
- History of or positive test result at Screening for human immunodeficiency virus (HIV)
- History of or positive test result at Screening for hepatitis C virus (HCV) antibody or hepatitis B virus (HBV)
- Possibility of neuromuscular weakness other than ALS
- Unspecified reasons that, in the opinion of the site Investigator, make the subject unsuitable for enrollment or unlikely to be able to complete, at a minimum, the Month 6 Visit
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by electrical impedance myography (EIM)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
EIM is an electrophysiological technique in which current is applied to a muscle of interest and resultant voltage and impedance are measured.
These measured parameters reflect the conductivity of underlying tissue and presumably the pathologic state of denervated muscle in an ALS participant
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by compound muscle action potential (CMAP)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
CMAP is a standard electrophysiological measure generated by maximally stimulating a nerve such that all muscle fibers innervated by the respective nerve are depolarized.
Reduction of CMAP amplitude reflects loss of motor axons and, therefore, is directly relevant to ALS.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number estimation (MUNE)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
Optional, to be administered at each site's Investigator's discretion.
MUNE is used to estimate the number of functioning motor units.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in electrophysiological measures as assessed by motor unit number index (MUNIX)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
MUNIX estimates functioning motor units within a muscle.
CMAP and surface electromyography potentials (surface interference patterns) are obtained at various levels of voluntary effort, and MUNIX is estimated using power and area of CMAP and surface interference patterns.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in muscle strength measures as assessed by hand-held dynamometry (HHD)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
HHD tests isometric strength of multiple muscles using standard participant positioning.
Approximately 10 muscle groups will be examined (per each side) in both upper and lower extremities.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in respiratory measures as assessed by slow vital capacity (SVC)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
Vital capacity will be measured by means of an SVC test, administered in the upright position.
Upright SVC will be determined by performing 3 to 5 measures, in accordance with criteria established by the American Thoracic Society and the European Respiratory Society.
|
Baseline to Month 6 and Baseline to Month 12
|
|
Longitudinal standardized mean change in functional measures as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Zeitfenster: Baseline to Month 6 and Baseline to Month 12
|
The ALSFRS-R has been demonstrated to predict survival.
The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills.
There are a total of 12 questions, each scored from 0 to 4 for a total possible score of 48 [Cedarbaum 1999], with higher scores representing better function.
|
Baseline to Month 6 and Baseline to Month 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Within-participant test-retest reliability between the 2 repeated measurements occurring on Day 1 and Day 7 for EIM
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for CMAP
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNE
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for MUNIX
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for HHD
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for SVC
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Within-participant test-retest reliability between the 2 repeated measurements for ALSFRS-R
Zeitfenster: Day 1 and Day 7
|
Day 1 and Day 7
|
|
Comparison between 6 and 12-month changes in exploratory measures with 18 and 24-month changes in ALSFRS-R and survival
Zeitfenster: Baseline to Month 24
|
Baseline to Month 24
|
|
Comparison between 6-month changes for muscle electrophysiological measures
Zeitfenster: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for muscle strength measures
Zeitfenster: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison between 6-month changes for functional measures
Zeitfenster: Baseline to Month 12
|
Baseline to Month 12
|
|
Comparison of molecular biomarkers with disease progression
Zeitfenster: Baseline to Month 12
|
Baseline to Month 12
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Stoffwechselerkrankungen
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Neuromuskuläre Erkrankungen
- Neurodegenerative Krankheiten
- Erkrankungen des Rückenmarks
- TDP-43 Proteinopathien
- Proteostase-Mängel
- Sklerose
- Motoneuron-Krankheit
- Amyotrophe Lateralsklerose
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 999AS003
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .